Literature DB >> 11783909

Comparative study of serotonin and bombesin in adenocarcinomas and neuroendocrine tumors of the colon.

E Seretis1, A Gavrill, N Agnantis, V Golematis, I E Voloudakis-Baltatzis.   

Abstract

The aim of this study was to investigate serotonin and bombesin expression in colorectal adenocarcinomas and neuroendocrine colorectal tumors to clarify their role in the progression of colon cancer. The investigation was carried out by electron microscope immunocytochemistry. The ultrastructural study revealed that some cases of colorectal adenocarcinomas were characterized by the presence of amphicrine cells containing endocrine granules and mucus granules. Poorly differentiated adenocarcinomas and liver metastases were poorly granulated compared with highly differentiated tumors. Neuroendocrine tumors nevertheless were characterized by the presence of numerous malignant neuroendocrine cells filled with secretory granules and mucus granules. Bombesin appeared to be located in enterochromaffin-like endocrine cells, which are primarily responsible for the production of serotonin. In colorectal adenocarcinomas there was an inverse correlation between serotonin levels and the degree of differentiation. High serotonin levels characterized colorectal adenocarcinomas with composite phenotype and colorectal neuroendocrine tumors. Increased bombesin expression was correlated with colorectal adenocarcinomas exhibiting poor histological grade and their liver metastases. In conclusion, the findings suggest that high serotonin levels may be an indicator of neuroendocrine differentiation, and bombesin may be a useful marker for colorectal adenocarcinomas with aggressive behavior,

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11783909     DOI: 10.1080/019131201753343485

Source DB:  PubMed          Journal:  Ultrastruct Pathol        ISSN: 0191-3123            Impact factor:   1.094


  9 in total

Review 1.  Neuroendocrine differentiation: The mysterious fellow of colorectal cancer.

Authors:  Britta Kleist; Micaela Poetsch
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

2.  Composite adenocarcinoma and large cell neuroendocrine carcinoma of the rectum.

Authors:  A Makino; S Serra; R Chetty
Journal:  Virchows Arch       Date:  2006-03-01       Impact factor: 4.064

3.  Plasma serotonin level is a predictor for recurrence and poor prognosis in colorectal cancer patients.

Authors:  Yan Xia; Dawei Wang; Nan Zhang; Zhihao Wang; Li Pang
Journal:  J Clin Lab Anal       Date:  2017-05-22       Impact factor: 2.352

4.  Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers.

Authors:  Ferenc G Rick; Stefan Buchholz; Andrew V Schally; Luca Szalontay; Awtar Krishan; Christian Datz; Andreas Stadlmayr; Elmar Aigner; Roberto Perez; Stephan Seitz; Norman L Block; Florian Hohla
Journal:  Cell Cycle       Date:  2012-07-01       Impact factor: 4.534

5.  Gastrin-releasing peptide receptor (GRPr) promotes EMT, growth, and invasion in canine prostate cancer.

Authors:  Said M Elshafae; Bardes B Hassan; Wachiraphan Supsavhad; Wessel P Dirksen; Rachael Y Camiener; Haiming Ding; Michael F Tweedle; Thomas J Rosol
Journal:  Prostate       Date:  2016-03-04       Impact factor: 4.104

6.  Depletion of serotonin and selective inhibition of 2B receptor suppressed tumor angiogenesis by inhibiting endothelial nitric oxide synthase and extracellular signal-regulated kinase 1/2 phosphorylation.

Authors:  Masanori Asada; Satoru Ebihara; Shinsuke Yamanda; Kaijun Niu; Tatsuma Okazaki; Ichiro Sora; Hiroyuki Arai
Journal:  Neoplasia       Date:  2009-04       Impact factor: 5.715

7.  Neuroendocrine neoplasms of gastrointestinal tract and secondary primary synchronous tumors: A systematic review of case reports. Casualty or causality?

Authors:  Rafael Parra-Medina; Paula Moreno-Lucero; Julian Jimenez-Moreno; Alejandra María Parra-Morales; Alfredo Romero-Rojas
Journal:  PLoS One       Date:  2019-05-14       Impact factor: 3.240

8.  Case report: potential treatment of metastatic amphicrine carcinoma of the rectum with FOLFOXIRI chemotherapy.

Authors:  Nobumasa Tamura; Yoshitaka Honma; Shigeki Sekine; Shunsuke Tsukamoto; Hidekazu Hirano; Natsuko Okita; Hirokazu Shoji; Satoru Iwasa; Atsuo Takashima; Ken Kato; Narikazu Boku
Journal:  Oxf Med Case Reports       Date:  2020-11-24

9.  Antidepressants in association with reducing risk of oral cancer occurrence: a nationwide population-based cohort and nested case-control studies.

Authors:  Chia-Min Chung; Tzer-Min Kuo; Shang-Lun Chiang; Zhi-Hong Wang; Chung-Chieh Hung; Hsien-Yuan Lane; Chiu-Shong Liu; Ying-Chin Ko
Journal:  Oncotarget       Date:  2016-03-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.